Dorsal Root Ganglion Stimulation for Lower Extremity Neuropathic Pain Syndromes: An Evidence-Based Literature Review.

Dorsal root ganglion stimulation (DRG-S) is a form of selective neuromodulation therapy that targets the dorsal root ganglion. DRG-S offers analgesia in a variety of chronic pain conditions and is approved for treatment of complex regional pain syndrome (CRPS) by the US Food and Drug Administration (FDA). There has been increasing utilization of DRG-S to treat various neuropathic pain syndromes of the lower extremity, although evidence remains limited to one randomized controlled trial and 39 observational studies. In this review, we appraised the current evidence for DRG-S in the treatment of lower extremity neuropathic pain using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria. The primary outcome was change in pain intensity after DRG-S compared to baseline. We stratified presentation of results based of type of neuropathy (CRPS, painful diabetic neuropathy, mononeuropathy, polyneuropathy) as well as location of neuropathy (hip, knee, foot). Future powered randomized controlled trials with homogeneous participants are warranted.

Key Summary Points

Introduction

The dorsal root ganglion (DRG) contains a collection of cell bodies of primary sensory, pseudo-unipolar neurons in the lateral epidural space of the spinal foramen [1]. DRG neurons are involved in the transduction of pain to the central nervous system (CNS), serving as a filter for propagation of afferent signals to the dorsal horn [1]. DRG stimulation (DRG-S) is a form of selective neuromodulation therapy that targets these primary sensory neurons and offers analgesia in a variety of chronic pain conditions [2].

DRG-S was first described in a case report in 1998, when a conventional spinal cord stimulator lead was used to target the DRG in a patient with discogenic low back pain and resulted in 69% pain relief [3]. In 2009, a DRG-specific stimulator lead was developed with a much smaller diameter, increased flexibility, and reduced contact size. This design allowed for precise targeting of nerve fibers that innervate the targeted painful regions without nonspecifically recruiting uninvolved dermatomes, even with areas that are typically more difficult to target with dorsal column spinal cord stimulation (SCS) like the groin and the foot. Because the DRG only has a thin layer of cerebrospinal fluid around it, DRG-S is achieved with a lower electrical current, is less affected by positional changes, possesses more stability, and offers superior electrical efficiency and energy consumption compared to dorsal column SCS [4]. However, DRG-S may have notable disadvantages including limited applicability in more widespread pain, difficulty of percutaneous placement, and difficulty or unfeasibility of placement in cases with neuroforaminal stenosis.

In 2011, the European Union and Australia approved the use of DRG-S after a multicenter study showed favorable efficacy in 76.5% of subjects with chronic, intractable neuropathic pain in trunk, sacrum, or lower limbs [5]. Subsequently, a multicenter, comparative, prospective, controlled efficacy trial showed a statistically significant higher rate of treatment success, improvement in quality of life, functional status, and psychological disposition in patients with complex regional pain syndrome (CRPS) and causalgia when treated with DRG-S in comparison to SCS treatment [6]. With these data, the US Food and Drug Administration (FDA) approved DRG-S in February of 2016 for the treatment of pain associated with CRPS of the lower extremities [7].

Although DRG-S has been practiced since 1998 [3], most of the evidence supporting DRG-S for neuropathic pain is recent. Furthermore, DRG-S is only approved for CRPS and/or peripheral causalgia in the groin and lower limb. Yet its utilization for other unapproved painful conditions of the lower extremity, such as painful diabetic neuropathy [8], persistent postsurgical pain [9], and mononeuropathies [10], is expanding and warrants evidence appraisal. Thus, the aim of this review is to assess the change in pain intensity in lower extremity neuropathic pain conditions after DRG-S, and to appraise the level of evidence for this outcome. We stratify presentation of results based of type of neuropathy, as well as location of neuropathy. Finally, we also highlight the mechanism of action of DRG-S in the treatment of neuropathic pain. This review is timely and relevant as it provides clinicians an updated appraisal of evidence for several clinical indications. In light of habituation [11] and loss of efficacy [12-14] from long-term dorsal column spinal cord stimulation, this review highlights yet another unique modality of neuromodulation that can be offered to patients to salvage analgesia, physical functionality, and patient satisfaction [15]. Finally, as researchers continue to elucidate the mechanisms of action from neuromodulation that lead to analgesia, DRG-S will be a primary focus due to the role of DRG neurons in pain transduction, afferent signal filtering, and windup phenomena [1].

Methods

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Search Strategy

A comprehensive search of several databases from each database’s inception to March 23, 2022, consisting of any language, was conducted. The databases included Ovid MEDLINE®, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced librarian (LJP) with input from the study’s principal investigator (RSD). Controlled vocabulary supplemented with keywords was used to search for DRG-S for treatment of lower extremity neuropathic pain. The search strategy listing all search terms used and how they are combined is available in the Supplementary Material.

Study Selection and Data Extraction

Included studies abided to the following criteria: any study design (case report, case series, retrospective or prospective observational studies, or randomized controlled trials) that involved patients receiving DRG-S for lower extremity neuropathic pain and included patient-reported measurements of pain intensity or pain relief after DRG-S. Exclusion criteria consisted of the following: non-peer-reviewed studies, review or meta-analysis articles, nonhuman studies, and unpublished clinical trials. The primary outcome was change in pain intensity after DRG-S compared to baseline. Specific outcome measures may consist of calculated or patient-reported percentage pain relief, as well as visual analog pain score or numeric rating scale score before and after DRG-S. Secondary outcomes included changes in physical functioning, emotional functioning, patient satisfaction, and adverse events.

Two authors (RSD and EK) independently selected abstracts along with full-text articles from the aforementioned databases, while a third author (AA) resolved any discrepancies (Fig. 1). The following data was extracted: (1) study characteristics (indication, DRG-S lead location, study design, funding), (2) participant demographics (sample size, average age, type of neurological impairment), (3) outcome of interest (change in pain intensity after DRG-S compared to baseline).

Fig. 1

PRISMA flow diagram for systematic review. Flowchart of the study selection process, inclusion and exclusion of studies, and reasons for exclusion are displayed

Assessment of Risk of Bias

The Newcastle–Ottawa Scale (NOS) was used to assess risk of bias in observational studies (containing over 10 participants) [5]. The Cochrane risk of bias assessment tool was used to assess risk of bias for randomized controlled trials (RCTs) [5, 16]. Risk of bias was only performed for studies assessing DRG-S for a specific neuropathic pain diagnosis (not solely location of pain). The NOS comprises the following three domains: selection, comparability, and exposure/outcome. Each specific NOS item can be assigned a maximum of 1 star, and a maximum of 2 stars can be given for the comparability domain. Studies with more stars for each domain have lower risk for bias for those respective domains. The Cochrane risk of bias tool assessed bias risk in the following domains: selection, performance, detection, attrition, reporting, and other biases. Each domain was assigned a grade of low risk, high risk, or unclear risk. For each included study, two authors (RSD and YH) independently assessed for risk of bias with a third author (AA) arbitrating any disputes.

Quality of Evidence

The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) quality assessment criteria [17] were used to assess the level of evidence for DRG-S use for each specific neuropathic pain diagnosis. GRADE certainty of evidence can be rated as one of the following four options: high, moderate, low, or very low. Although RCTs receive a high-level score, the level of evidence can be downgraded on the basis of deficiencies in domains of risk of bias [18], inconsistency [19], indirectness [20], imprecision [21], and publication bias [22].

Results

Complex Regional Pain Syndrome

Per the Budapest criteria, CRPS is a diagnosis characterized by pain that is disproportionate to the inciting event associated with abnormal sensory (allodynia), as well as vasomotor, sudomotor, and/or motor/trophic symptoms [23]. One RCT [6] and 11 observational studies [5, 10, 16, 24–31] described DRG-S for treatment of pain from CRPS (Table 1). The ACCURATE RCT [6] demonstrated that DRG-S was non-inferior (p < 0.0001) and superior (p < 0.0004) to traditional dorsal column SCS through 12 months of follow-up for lower extremity CRPS pain intensity. When the primary endpoint was assessed at 3 months (50% reduction in visual analog scale [VAS] from pre-implant levels), 56 of 69 (81.2%) participants receiving DRG-S achieved treatment success versus 39 of 70 (55.7%) participants receiving dorsal column SCS (statistical non-inferiority p < 0.0001, statistical superiority p < 0.0004). Similarly, 49 of 66 (74.2%) participants in the DRG-S cohort achieved the primary endpoint at 12 months versus 35 of 66 (53.0%) participants in the SCS cohort (statistical non-inferiority p < 0.0001, statistical superiority p < 0.0004). The DRG-S cohort also reported higher quality of life, functional status, and emotional functioning metrics compared to those receiving dorsal column SCS. Importantly, participants receiving DRG-S reported less postural variation of paresthesias and less non-specific, extraneous stimulation in non-painful areas compared to those receiving dorsal column SCS.

Table 1

Summary of studies on complex regional pain syndrome

Author, year	Country	Study design	Study funding	No. of subjects	Diagnosis	Mean age (years)	Intervention	Outcomes
Van Bussel et al. (2015) [32]	Netherlands	Case report	No funding	1	CRPS type I of the right knee	48	DRG-S L2, L3, L4	After successful trial with 3 leads (covering 90% of the painful area of her knee), DRG stimulator was implanted. At 3 months, the entire painful area was covered, and pt reported a NRS of 1–2. Movement of right knee improved
Van Buyten et al. (2015) [29]	Australia, Netherlands, Belgium	Case series	Sponsored by Spinal Modulation, Inc.	8	CRPS	43.9 ± 5.6	DRG-S	All 8 pts had some degree of pain relief and improvement in function. 1 month after implantation, there was a significant reduction in pain by 38% on average. Pain relief persisted at 12 months in most subjects. In some subjects, edema and trophic skin changes associated with CRPS were improved
Liem et al. (2015) [5]	Netherlands, Australia	Prospective noncomparative	Sponsored by Spinal Modulation	18	Chronic neuropathic pain in the trunk or lower limbs: FBSS (n = 16), CRPS (n = 8), peripheral nerve damage (n = 1), pain after vascular stenting (n = 1), postsurgical neuropathic pain (n = 6)	54.3 ± 13.3	DRG-S	Pain reduced by 56% at 12 months and 60% of subjects reported more than 50% improvement. QoL and mood were also improved, and subjects reported high levels of satisfaction. Excellent and ongoing pain–paresthesia overlap was reported through 12 months
Garg et al. (2015) [30]	USA	Case report	No funding	1	CRPS	43	DRG-S	Pt reported > 70% pain relief. VAS decreased from 8/10 to 4/10, with ability to perform all activities of daily living
Van Bussel et al. (2018) [33]	Netherlands	Prospective, observational crossover cohort	No funding	12	CRPS confined to the knee	38.7	DC SCS vs. DRG-S	After receiving DC SCS and DRG-S during a trial period of 16 days, pts were asked which one they preferred. Pts with a successful trial period had fully implantable system. At the end of the trial period, 10 pts (83.3%) preferred DRG-S and 2 (16.7%) DC SCS
Yang et al. (2017) [34]	USA	Case series	No funding	2	CRPS in the lower extremity refractory to DC stimulation	43 and 50	DRG-S	Pt 1 had 90% pain reduction with significant gait improvement during the trial and received an implant Pt 2 had hybrid system with 2 IPGs when DRG-S system added to the existing SCS. She reported an immediate improvement in pain. Her pain scores were at the lowest with the DRG-S on by itself At 8 months follow-up, both pts reported sustained pain improvement and retained their functional gains
Deer et al. (2017) [6]	USA	RCT	Study sponsored by Spinal Modulation, LLC	Total: 152 SCS: 76 DRG-S: 76	CRPS or causalgia in lower extremities	DRG: 52.4 SCS: 52.5	DRG-S	Pts had 50% or greater decrease in VAS score from baseline. The percentage of pts receiving ≥ 50% pain relief was greater in the DRG arm (81.2%) than in the DC SCS arm (55.7%) at 3 months. Device-related SAEs were not different in the 2 groups. DRG-S arm demonstrated greater improvements in QoL and psychological disposition. Pts using DRG-S reported less postural variation in paresthesia and reduced extraneous stimulation in non-painful areas
Skaribas et al. (2017) [28]	USA	Case series	No funding	5	Chronic foot pain—CRPS I (n = 3), CRPS II (n = 2)	Range: 49–71	DRG-S S1	All 5 pts had severe pain (8–10 NRS) and significant loss of function and QoL (2–4 NRS) before the procedure. All had excellent (0–3 NRS) pain relief and functional improvements (8–10 NRS) with a single S1 DRG electrode trial, and all 5 had permanent implantation. Benefits were maintained at 1, 2, 3, and 6 months
Goebel et al. (2017) [35]	UK	Case report	No funding	1	CRPS 2 years after mid-tibial amputation	Not reported	DRG-S L4	SCS did not provide pain relief in the stump, but DRG-S led to modest pain relief, and over time, substantial pain relief
Huygen et al. (2019) [25]	Netherlands	Prospective noncomparative	Sponsored by Abbott Laboratories	66	Chronic, intractable pain of trunk or lower limbs (FBSS, peripheral nerve injury, CRPS)	52 ± 11.5	DRG-S	Permanent implants were placed in 86.2% of pts. After 12 months of treatment, average pain in primary area of pain decreased from 8.0 to 4.1 cm, and 49% of subjects had ≥ 50% reduction in VAS. Functional capacity increased, and mood and QoL improved
Piedade et al. (2019) [27]	Germany	Prospective noncomparative	No funding	18	Postsurgical pain (n = 5), CRPS (n = 5), postherpetic neuralgia (n = 3), nerve injury (n = 5), phantom pain (n = 1)	50.6 ± 9.68	Cervical and upper thoracic DRG-S	20 pts were trialed and 20 received permanent stimulator. The average pain relief at 3 months compared to the baseline was 60.9% (mean VAS 8.5–3.2). 77.8% of pts reported pain relief of at least 50% after 3 months. One pt developed transient paresis of the arm caused by the procedure but completely recovered within 3 months
Gravius et al. (2018) [24]	Germany	Comparative non-randomized study	Investigator-initiated study with funding from Abbott	Total: 24 DRG-S: 12 Control: 12	CRPS I/II	70 ± 9.3	DRG-S L4	After 3 months of DRG-S, pain significantly decreased. Sleep and mood improved post-DRG-S. Significantly increased serum values of pro-inflammatory markers were detected pre- and post DRG-S for high-mobility group box 1, TNFα, IL-6, and leptin. IL-1β was significantly elevated pre-L4 DRG-S, but not post-treatment. Elevated anti-inflammatory IL-10 significantly decreased after 3 months in serum, while saliva oxytocin concentrations increased in CRPS subjects after L4-DRG-S
Morgalla et al. (2018) [36]	Germany	Prospective with single arm	No funding	62	Neuropathic pain in hands, back, legs, knees, and feet including CRPS	56.8	DRG-S	Results after 3 years post-implant: median VAS decreased from 8 to 4. The PDI decreased from 45 to 23. The PCS decreased from 34 to 21. The BPI dropped from 73 to 30. The BDI decreased from 36 to 21. 14 pts had AEs (27.4%)
Hunter et al. (2018) [37]	USA	Multicenter retrospective registry study	No funding	217	Various neuropathic pain etiologies CRPS (N = 113)	54.5	DRG-S	DRG-S was found to be an effective treatment in all evaluated diagnoses, most of which had statistically significant improvements in pain. The most important predictor of trial success was the amount of painful area covered by paresthesias during the programing phase. The number of leads had a direct and indirect impact on trial success
Deer et al. (2019) [38]	USA	Retrospective RCT sub-analysis	No funding	Total: 75 DRG-S: 41 SCS: 34	CRPS I or II	Not reported	DRG-S	Painful areas covered by paresthesia were significantly lower for DRG-S compared to DC SCS pts (13% vs. 28%). The amount of paresthesia produced outside the painful areas was significantly lower in DRG-S compared to DC SCS. On average, unrequired paresthesia was only 20% of the pts’ total painful body surface area in the DRG-S arm compared to 210% in the DC SCS group
Kinfe et al. (2019) [39]	Germany	Case series	Investigator-initiated study with funding from Abbott	12	CRPS	63.6	DRG-S L4	Transcriptomic analysis showed that 21 genes were significantly changed after DRG-S. 7 genes (TLR1, FFAR2, IL1RAP, ILRN, C5, PKB, and IL18) were downregulated and 14 genes (CXCL2, CCL11, IL36G, CRP, SCGB1A1, IL17F, TNFRSF4, PLA2G2A, CREB3L3, ADAMTS12, IL1F10, NOX1, CHIA, and BDKRB1) were upregulated
Kinfe et al. (2020) [16]	Germany	Case series	Investigator-initiated study with funding from Abbott	12	CRPS	69 ± 9	DRG-S L4	At baseline, pts showed significantly increased thresholds for WDT, MDT, and VDT and exaggerated WUR. After 3 months pain parameters trended towards normalization of sensitivity accumulating to a significant overall normalization for pain sensitivity. With the exception of WDT, all non-nociceptive QST parameters remained unchanged. Overall change of non-nociceptive detection was negligible. Reduction of pain summation (WUR) correlated significantly with pain reduction after 3 months of stimulation
Pinckard-Dover et al. (2020) [31]	USA	Case report	No funding	1	CRPS	17	DRG-S L4 L5	Pt had 100% relief after 4 days of treatment that was sustained at 30 months follow-up. Her pain improvement allowed her to start PT
Levy et al. (2020) [11]	USA	Retrospective RCT sub-analysis	No funding	Total: 152 DRG-S: 73 SCS: 72	CRPS I or II	52.5 ± 12.7	DRG-S	A modified intention-to-treat analysis showed that for both groups, mean PPR was significantly greater at end-of-trial (DRG-S = 82.2%, SCS = 77.0%) than other follow-ups. After permanent DRG system was placed, none of the time points were significantly different from one another in PPR. DRG-S resulted in more stable pain relief through 12 months, while DC SCS demonstrated therapy habituation at 9–12 months
Ghosh et al. (2021) [40]	USA	Case series	No funding	4	CRPS	30; 28; 52; 44	Concurrent DRG-S and DC SCS	All pts reported superior pain relief and function with SCS and DRG-S, as compared to DRG-S alone. The average NRS decreased from 7 in the regions not covered by SCS to 3 after DRG-S was placed, and to 1.25 with concurrent SCS and DRG-S
Pendem et al. (2021) [41]	USA	Case report	No funding	1	Right foot CRPS	60	DRG-S L5/S1	Pt had 90% pain reduction. On his 6 months follow-up appointment, the pt mentioned rare pain flare-ups of 8–9/10 on the NRS and had weaned off opioids. Pain score has remained 1/10 at most times
Hagedorn et al. (2021) [2]	USA	Retrospective	No funding	93	CRPS or chronic lumbar radiculopathy	59.89 ± 14.12	DRG-S	Pts prescribed chronic opioids at the time of DRG-S implantation had a higher likelihood of less than 50% pain relief and 80% pain relief at 1, 3, and 12 months follow-up visits
Chapman et al. (2021) [42]	USA	Case series	No funding	3	CRPS with peripheral arterial disease	44; 55; 69	DRG-S	All pts had significant reduction in pain with DRG-S, and improved blood flow, avoiding or limiting amputation. PVR improved dramatically with DRG-S in pt 1. Better improvement in TcPO2 was seen with the DRG-S trial compared to DC SCS trial in pt 2. Pt 3 had an increase in walking distance and demonstrated long-term efficacy and limb salvage at 32 months post-implantation

AE adverse event, BPI Brief Pain Inventory, BDI Beck Depression Inventory, CRPS complex regional pain syndrome, DC dorsal column, DRG dorsal root ganglion, DRG-S dorsal root ganglion stimulation, FBSS failed back surgery syndrome, IL interleukin, IPG implantable pain generator, MDT tactile/mechanical detection threshold, NRS numeric rating scale, PDI Pain Disability Index, PCS Pain Catastrophizing Scale, PT physical therapy, PVR pulse volume recordings, QoL quality of life, SCS spinal cord stimulator, TNF tumor necrosis factor, VAS visual analogue scale, pts pts, VDT vibration detection threshold, WDT warmth detection threshold, WUR pain summation

Findings from the pivotal ACCURATE trial are further supported by data from five prospective observational studies [5, 16, 24–26], four cases series [10, 27–29], and two case reports [30, 31]. In total, these observational studies comprised 148 participants with CRPS type I and 188 participants with CRPS type II. Huygen et al. [25] reported a multicenter, prospective study that enrolled participants with failed back surgery syndrome, peripheral neuropathy, and CRPS. Eleven CRPS type I participants (46.8%) and 13 CRPS type II (43.7%) participants reported pain relief at 12 months. Gravius et al. [24] conducted a prospective study on participants with CRPS type I, who achieved 61.3% pain reduction along with improved mood and sleep metrics at 3 months post-implant. Morgalla et al. [36] performed a prospective study that enrolled 62 participants with CRPS type II with 51 receiving permanent DRG-S. The study reported improvement in mean VAS scores (8.0–4.5), function (Brief Pain Inventory, 76–30; Pain Disability Index, 45–23), and mood (Beck Depression Inventory, 36–21) at 36-month follow-up. Liem et al. [5] reported that eight participants with CRPS type I with permanent DRG-S had reduced pain by 56% at 12 months. Knife et al. [16] studied the effects of DRG-S on quantitative sensory threshold (QST) testing in participants with CRPS type I, and reported improved warmth, tactile, and vibration QSTs along with normalization of pain sensory thresholds after DRG-S implant. These positive outcomes from prospective observational studies supporting DRG-S for CRPS are further reinforced by data from case series and reports [10, 27–31].

In summary, the evidence base for DRG-S for the treatment of CRPS type I or CRPS type II includes one RCT and 11 observational studies reporting outcomes between 3 and 36 months. There was low-quality GRADE evidence that DRG-S reduced pain and disability in participants with CRPS type I or CRPS type II. According to the GRADE approach, the evidence quality was initially rated as “moderate quality” evidence based on the ACCURATE trial [6]. With inclusion of observational studies, this was downgraded to “low quality” because of risk of bias, imprecision, and indirectness (Fig. 2 and Table 2). Furthermore, the participants in these studies were heterogenous. Aside from the ACCURATE trial, the sample size of participants in each study was low and underpowered to detect significant differences between the groups.

Fig. 2

Risk of bias summary. Risk of bias scores for the single randomized controlled trial are displayed on the basis of the authors’ judgements of each item. Green signifies low risk of bias, red signifies high risk of bias, and yellow signifies unclear risk of bias

Table 2

Quality rating for the observational studies using the Newcastle–Ottawa Scale

Author	Selection	Comparability	Exposure/outcome
Gravius 2019	**	–	*
Huygen 2019	**	–	**
Skaribas 2019	*	–	–
Morgalla 2017	**	–	*
Morgalla 2019	**	–	*
Liem 2015	**	–	**
Koetsier 2020	**	–	**

Quality of cohort and case control studies was determined using the Newcastle–Ottawa Scale, which evaluates three categories: selection (maximum 4 stars), comparability (maximum 2 stars), and outcome (maximum 3 stars)

Painful Diabetic Neuropathy

Painful diabetic neuropathy (PDN) is defined as a symmetric, length-dependent sensorimotor polyneuropathy attributable to metabolic and microvascular alterations as a result of chronic hyperglycemia exposure and cardiovascular risk covariates [43]. This can be a progressive and debilitating condition that can cause painful paraesthesias, with only one-third of patients typically achieving clinically significant pain relief from conventional therapy [44]. Neuromodulation interventions are becoming more common modalities utilized in the treatment of PDN [45-47]. Two retrospective studies [8, 48] and one case report [49] described DRG-S for treatment of PDN (Table 3).

Table 3

Summary of studies on painful diabetic neuropathy

Author, year	Country	Study design	Study funding/COI	No. of subjects	Diagnosis	Mean age (years)	Intervention	Outcomes
Eldabe et al. (2018) [8]	Australia, Netherlands, Germany, UK, Sweden	Retrospective	Sponsored by Abbott	10	Refractory PDN	65.2 ± 8.8	DRG-S	Seven pts had permanent stimulator implants, but two pts subsequently required explantation because of failure to locate primary pain area and personal reasons. For 5 pts that proceeded to clinical follow-ups, baseline VAS was reduced by an average of 63.9% post-implant. For 4 pts with 12 months follow-up data, mean relative reduction was 64.2%
Falowski et al. (2019) [48]	USA	Retrospective, multicenter	Sponsored by Abbott	8	Peripheral neuropathy in lower extremities (chronic radiculopathy n = 1, PDN n = 2, other n = 5)	64.8 ± 10.2	DRG-S L4–S1	Pain reduction at 6 weeks follow-up by 79.5 ± 18.8%. Relief ranged from 42.86% to 100%; 2 pts had complete resolution of pain; 7/8 pts had greater than 50% pain relief. Three pts had significantly decreased pain medication use and 4 stopped
Chapman et al. (2020) [49]	USA	Case report	No funding	1	PDN	61	DRG-S 7-day trial	Pain, disability, general health, and QoL measures improved significantly. Significant pain relief in the low back and feet, near resolution of other PDN-related symptoms, including numbness, bluish discoloration, and allodynia of both feet. Pt had functional and psychological benefits with a single-sided lead. Unilateral T12 and S1 DRG-S leads resulted in symmetric improvement of PDN symptoms

AE adverse event, COI conflict of interest, DRG-S dorsal root ganglion stimulation, PDN painful diabetic neuropathy, pts patients, QoL quality of life

Eldabe et al. [8] performed a retrospective study of ten participants with chronic intractable PDN who trialed DRG-S using up to four quadripolar percutaneous leads between L2 and L5. Of the seven patients who proceed to implantation, five patients followed to six months reported a mean VAS reduction of 49.4 mm, and four patients followed to twelve months reported a mean VAS reduction of 48.2 mm. Overall, this study reported a 70% success rate for trial-to-implant ratio and clinically significant pain relief in most patients followed to 12 months. Similarly, Falowski et al. [48] performed a retrospective analysis in which eight patients with chronic intractable peripheral neuropathy of the lower extremities underwent DRG-S. Two of these patients had PDN, with one achieving over 70% pain relief after bilateral L5 DRG lead placement after 6 weeks, and the other patient experiencing 100% pain relief after lead placement unilaterally at the left L4 and L5 levels. Finally, Chapman et al. [49] published a case report of a 61-year-old man with PDN and low back pain. He underwent a 7-day trial of unilateral DRG stimulation at the right T12 and S1, which allowed the untreated side to serve as a comparison. This resulted in significant pain relief in both feet and low back pain, with a VAS reduction from 8 to 1 cm for his back pain, and from 9 cm to 0 for his feet pain. This patient also had improvements in quality of life, physical function, emotional function, ambulation, skin color, and numbness in his feet.

In summary, the available evidence for DRG-S for PDN includes two retrospective case series and a case report, with study outcomes between 7 days and 12 months. Overall, there was very low-quality GRADE evidence that DRG-S reduced pain intensity for participants with PDN. Criteria that lowered the evidence level included study methodology limitations, indirectness due to varying patient diagnoses, and imprecision from small sample sizes.

Mononeuropathy and Focal Neuropathy

One retrospective study [50] and two case series [48, 51] reported outcomes from DRG-S in participants with focal neuropathy or mononeuropathy (Table 4). Kretzschmar et al. [50] reported that 23 of 27 participants with traumatic upper extremity and lower extremity injury underwent DRG-S implant after a successful DRG-S trial providing greater than 50% pain relief. At 36 months follow-up, pain intensity was reduced by a mean of 73%. Functional scores for Short Form-12 mental component summary and Short Form-12 physical component summary were improved from 34.1 to 43.6 and 42.3 to 50.0, respectively. Twenty of 21 participants were opioid-free at 36 months.

Table 4

Summary of studies on mononeuropathy and focal neuropathy

Author, year	Country	Study design	Study funding/COI	No. of subjects	Diagnosis	Mean age (years)	Intervention	Outcomes
Zuidema et al. (2014) [51]	Netherlands	Case series	No funding	3	Neuropathic groin pain	36, 46, 39	DRG-S T11–L3	Case 1: After complete pain relief with trial, patient was implanted with DRG-S and at the follow-up period of 3 months, pain relief remained 100% (VAS 0 mm) Case 2: Pain relief remained at 100% at 3 months Case 3: VAS decreased to 1 cm within 1 week and was maintained at 2 months (90% pain relief)
Morgalla et al. (2017) [10]	Germany	Prospective with single arm	Investigator-initiated grant	34	Neuropathic groin pain from nerve injury of ilioinguinal or iliohypogastric nerve	50.4	DRG-S	30/34 pts were converted to permanent DRG-S. Results after 3 years were VAS decreased from median of 58 to 54.5. The PDI decreased from 548 to 523. The PCS changed from 531 to 516. The BPI dropped from 576 to 530. The BDI decreased from 517 to 57. Total of 5 patients had complications (16.7%)
Morgalla et al. (2019) [52]	Germany	Prospective with single arm	Multiple institutional funding sources	12	Unilateral localized neuropathic pain in the lower limbs or inguinal region	51.8 ± 6.05	DRG-S	At 1 and 6 months follow-ups, N2–P2 amplitudes were significantly greater and NRS scores significantly lower compared to baseline. There was a negative correlation between LEP amplitudes and NRS scores
Martin et al. (2020) [53]	UK	Retrospective	Grant funding from National Institute for Health Research Oxford Biomedical Research Centre	Total: 14 Single L3 lead: 8 Single L4 lead: 1 L3 and L4 leads: 3	Chronic neuropathic knee pain	49.2	DRG-S	Median preoperative NRS was 8.5 and median postoperative NRS was 2. The median improvement in pain score was 80%. All 12 pts were responders. Median coverage of pain area was 85%. 2 pts had their leads explanted: 1 for non-efficacy, and 1 for repeated electrode displacement
Schu et al. (2015) [9]	Germany (but other European states also involved)	Retrospective	No funding	29	Chronic groin pain: Post-herniorrhaphy (N = 12) and other etiology	> 18 years	T2–L2 DRG-S	25 pts (86.2%) received fully implantable DRG-S, average follow-up period was 27.8 ± 4.3 (SEM) weeks. The mean pain reduction was 71.4 ± 5.6%, and 82.6% (19/23) of pts experienced > 50% pain reduction at the last follow-up. A subgroup analysis of post-herniorrhaphy cohort also showed significant improvement
Hunter et al. (2017) [54]	USA	Case series	No funding	4	Post-amputation pain	59, 32, 67, 30	Selective stimulation of the DRG-S	Stimulating 1 or more DRG(s) produced paresthesia patterns that were contradictory to known dermatomal patterns. Upon completion of a 1-week trial, all 4 pts reported 60–90% pain relief, with coverage of the painful areas, and had permanent implant

BPI Brief Pain Inventory, BDI Beck Depression Inventory, COI conflict of interest, DRG dorsal root ganglion, DRG-S dorsal root ganglion stimulation, LEP laser-evoked potentials, PCS Pain Catastrophizing Scale, PDI Pain Disability Index, SCS spinal cord stimulation, SEM standard error of the mean, VAS visual analog scale

Zuidema et al. [51] reported two cases of focal neuropathy of the lateral femoral cutaneous nerve (LFCN), and ilioinguinal nerve and genitofemoral nerve (IGN and GFN). After DRG-S implant, the participant with LFCN neuropathy reported 90% pain relief after 2 months. The participant with neuropathy at the IGN and GFN reported 100% pain relief at 3 months after DRG-S. Finally, Falowski et al. [48] reported one case of chronic intractable left L5 radiculopathy that was treated with DRG-S. The participant reported 100% pain relief at 6 weeks and had stopped taking baseline non-steroidal anti-inflammatory drugs.

Other Idiopathic Peripheral Neuropathies and Polyneuropathies

A prospective pilot study by Koetsier et al. [55] evaluated DRG-S on nine patients with intractable large fiber polyneuropathy (Table 5). Etiologies included type II diabetes, chemotherapy-induced peripheral neuropathy (CIPN), chronic inflammatory demyelinating polyradiculoneuropathy, and idiopathic. In seven of the nine patients who underwent DRG-S implantation, daytime pain at 6 months decreased from 7.0 to 3.0, nighttime pain decreased from 5.4 to 1.0, and peak pain decreased from 9.0 to 4.0. The etiologies of polyneuropathy in this study were heterogeneous and there was no subgroup analysis between etiologies and outcome measures. However, the authors reported that the two patients with PDN had similar pain relief in comparison to other etiologies.

Table 5

Summary of studies on idiopathic peripheral neuropathy and polyneuropathy

Author, year	Country	Study design	Study funding/COI	No. of subjects	Diagnosis	Mean age (years)	Intervention	Outcomes
Deer et al. (2013) [57]	USA	Prospective non-comparative	Sponsored by Spinal Modulation, Inc.	10	Chronic intractable pain of the trunk and/or limbs	Male: 52 ± 5 Female: 39 ± 4	DRG-S	There was a mean 70% reduction in pain. 8/9 pts had > 30% reduction in pain, and 7/9 pts reduced their pain medication utilization. Pain relief in leg, back, and foot was also observed. No device-related AEs were reported
Maino et al. (2017) [58]	Switzerland	Case report	No funding	1	Painful small fiber neuropathy	74	DRG-S	After a positive 10-day trial, a permanent stimulator was implanted. At 20 months post-implantation, pt continued to have stimulation-induced paresthesia covering the entire painful area. Pain decreased from 8 to 4
Mata et al. (2020) [59]	USA	Case report	No funding	1	Frostbite with refractory burning and pain in the foot	65	DRG-S	Pt had significant improvement in his pain and continued to have 90% improvement at 2 years. He was weaned off oxycodone, amitriptyline, and gabapentin; his fentanyl patch was lowered to 25 μg every 72 h and he was able to return to work
Kretzschmar et al. (2021) [60]	Germany	Case report	No funding	1	Central post-stroke pain in the lower extremity after medullary infarction	53	DRG-S	Pt was successfully weaned off opioids after implantation
Koetsier et al. (2021) [55]	Switzerland	Prospective non-comparative	No funding	9	Chronic painful polyneuropathy in the lower limbs	63.2 ± 8.7	DRG-S L5 and S1	8/9 pts had a successful DRG-S trial, and 7 underwent implantation. Daytime pain decreased from a median (IQR) NRS score of 7.0 (5.9–8.3) to 2.0 (1.0–3.5) and 3.0 (1.6–4.9) in the 1st week and at 6 months after implantation. Similar effects were observed for nighttime and peak pain scores
Grabnar et al. (2021) [61]	USA	Case report	No funding	1	CIPN	50	DRG-S	DRG-S resulted in 100% pain relief which persisted at 3 years after placement
Roybal et al. (2021) [62]	USA	Case report	No funding	1	Acute neuropathic pain from acute HZ infection	61	DRG-S left S1 dorsal	After 1 month of pain refractory to treatment, DRG-S significantly decreased pain despite ongoing cutaneous manifestations of HZ
Horan et al. (2021) [63]	Denmark	Cohort, multicenter	No funding	43	Chronic neuropathic pain in upper extremity, lower extremity, or trunk	Trial: 43 ± 10 Implant: 42 ± 10	DRG-S	33 subjects were implanted. At 12 months, 58% of pts were still implanted; 42% had fully functional systems. NRS score was reduced from mean 6.8 to 3.5 and worst NRS score was reduced from mean 8.6 to 6.0 at 12 months follow-up. PCS decreased from mean of 32 to 15. Thirteen pts experienced complications related to leads (39% of implanted systems). In 4 pts (12%), lead removal left fragments in the root canal, and 3 pts suffered permanent nerve damage during attempts to replace broken leads

AE adverse event, CIPN chemotherapy induced peripheral neuropathy, COI conflict of interest, DRG-S dorsal root ganglion stimulation, HZ herpes zoster, IQR interquartile range, NRS numerical rating scale, PCS pain catastrophizing scale, pts patients, SCS spinal cord stimulation

Grabnar et al. [56] reported DRG-S in a 50-year-old woman with a history of breast cancer and lower extremity CIPN. She had a successful 7-day DRG-S trial, achieving a decrease in VAS from 8 to 0, and her Douleur Neuropathique 4 (DN4) questionnaire score improved from 8/10 to 2/10. She has persistent pain relief 3 years later.

Overall, the body of literature for use of DRG-S in polyneuropathy is limited to case reports and prospective observational study data. There was very low-quality GRADE evidence supporting DRG-S use in reducing pain and impairment in polyneuropathy. According to the GRADE approach, the evidence quality for Koetsier et al. was initially considered as low, but ultimately was downgraded on the basis of indirectness with differing diagnoses of participants, notable methodological biases, imprecision from small sample sizes, and inclusion of case reports.

Groin Pain

A systematic review concluded that there is moderate evidence for DRG-S in treatment of neuropathic pain of the trunk or lower extremities, although it does not specifically address pain confined to the groin [64]. Advantages of DRG-S over dorsal column SCS include targeting discrete areas, maintenance of efficacy with postural changes, and lack of paresthesia in non-targeted areas [6]. These unique features of DRGS posit it to be especially useful in post-herniorrhaphy groin pain, a notoriously challenging region to target via dorsal column SCS [65-67]. Inguinal hernia repair is a common procedure, and the literature suggests that between 5% and 25% of patients will manifest post-herniorrhaphy neuralgia [65, 68]. Thus, the frequency of hernia repair procedures along with the percentage of patients afflicted by post-herniorrhaphy neuralgia suggests a need for escalation of treatment options in patients not amenable to medical management only. In addition to post-herniorrhaphy groin pain, DRG-S may be a viable and effective treatment option for other painful etiologies affecting the groin such as CRPS, structural damage to the ilioinguinal, iliohypogastric, or genitofemoral nerves, post-vasectomy neuralgia, and chronic pelvic pain syndrome [66].

Schu et al. [9] conducted a multicenter, retrospective study of patients who underwent DRG-S for chronic intractable, neuropathic groin pain. Of the 29 patients who underwent DRG-S trial, 25 achieved 50% or greater pain reduction and underwent implantation. After a median follow-up of 26 weeks, 19 of 23 patients achieved greater than 50% reduction in pain intensity, with 11 of 19 patients reporting pain reduction greater than 80%. Similarly, another multicenter, retrospective study [68] reviewed 32 patients with chronic neuropathic groin pain and reported a mean reduction of 68.6% in NRS after DRG-S trial. Lead placement was performed at T12–L2 for most patients; however, the range of levels targeted included T9–S3. After analysis of varying lead arrays, the authors recommended that for post-herniorrhaphy patients, the optimal lead arrangement was either T12, L1, or L2 in combination with either L2 or L3 [68]. These findings are concordant with Morgalla et al. [10] reporting promising long-term results at 3-year follow-up in a prospective cohort study of 34 patients with chronic groin pain treated with DRG-S.

In summary, there is limited evidence pooled from both retrospective and prospective observational studies highlighting that DRG-S may be an effective treatment modality for chronic, intractable neuropathic groin pain with most patients obtaining relief when leads were placed at the T12–L2 level.

Knee Pain

Total knee arthroplasty (TKA) is one of the most common surgeries with over 700,000 performed in the USA annually. Unfortunately, 8–34% of post-TKA patients experience a complicated postsurgical course with persistent neuropathic postsurgical pain (NPP) [66, 67]. DRG-S may offer a viable treatment modality for patients with persistent neuropathic knee pain refractory to conventional medical management.

Hunter et al. [68] conducted a multicenter, retrospective registry study of DRG-S for neuropathic knee pain. Their results of 23 patients showed 66.1% mean pain relief and 30% of patients reported greater than 80% improvement in pain intensity. Their analysis of a variety of lead combinations found that DRG-S provided a pain score reduction of 86.4% when targeting the L4 DRG and 74% reduction when targeting the L3 DRG. Thus, the study recommended targeting both the L3 and L4 DRG for treatment of neuropathic knee pain; if the implanting provider desires to only place one lead, the authors reported that preference should be given to L4 DRG placement given its slightly higher efficacy in pain reduction compared to L3 DRG placement [68].

Similarly, Martin et al. [69] conducted a secondary analysis of a prospective study of 14 patients with neuropathic knee pain. Of 14 patients, 12 had a successful trial and received a permanent implant, including five patients with postsurgical knee pain and seven patients with pain secondary to traumatic injury. At a mean follow-up of 34 months, they found an 80% median improvement in pain score and a 54% mean reduction in oral morphine equivalents. Lead placement was determined during DRG-S trial, with eight patients achieving a positive response to L3 DRG-S alone, one patient from L4 DRG-S alone, and three patients requiring combined L3 and L4 DRG-S to adequately cover their painful region.

In a prospective, crossover study comparing DRG-S and dorsal column SCS for CRPS confined to the knee, 10 of 12 (83%) patients preferred DRG-S while two of 12 (17%) patients chose to proceed with dorsal column SCS [33]. The lead placement for DRG-S was at both the L3 and L4 DRGs for all patients [33]. This crossover study concluded that in patients with chronic CRPS confined to the knee, DRG-S is an effective treatment and that DRG-S was preferred over dorsal column SCS in 83% of patients.

There are currently no RCTs analyzing DRG-S for knee pain, although the observational studies outlined above provide low-quality evidence supporting DRG-S of the L3 and L4 DRG as a treatment option for patients with refractory neuropathic pain confined to the knee.

Foot Pain

Painful conditions of the foot commonly treated with DRG-S include CRPS and phantom limb pain. Sensory innervation for the foot is primarily from the L4, L5, and S1 nerve roots. Foot pain may be difficult to target with traditional dorsal column SCS compared to DRG-S [49]. It is postulated that there is convergence between DRGs at adjacent levels, so placing a lead at one level may result in paresthesias and pain relief at adjacent levels [28, 70]. As outlined above, the ACCURATE trial [6] and another prospective observational study by Liem et al. [5] highlight evidence for DRG-S in treating foot pain.

For chronic foot pain, the most common levels of DRG-S placement are at the L4, L5, and S1 DRGs. In one case of CRPS, recurrence developed after left-sided transtibial amputation and subsequent neuroma excision. Dorsal column SCS was attempted, although the patient did not experience adequate paraesthesia coverage of the stump [35]. DRG-S was subsequently attempted at the left L4 DRG with 75% coverage of stump pain. At 17-month follow-up, the patient reported 60% pain relief with DRG-S. In a case series by Skaribas et al. [28] five patients with CRPS of the foot and prior back surgery underwent S1 DRG-S. The single S1 DRG electrode resulted in pain relief of the entire foot and all five patients achieved substantial improvement in pain intensity and quality of life at 6-month follow-up [28].

Discussion

Summary of Evidence

This review highlights the use of DRG-S for a variety of neuropathic pain syndromes of the lower extremity. The highest level of evidence is demonstrated with DRG-S use for CRPS of the lower extremity based on results from the ACCURATE trial [6]. However, the evidence base overall was downgraded to “low-quality” evidence because of risk of bias, imprecision, heterogeneity, and indirectness from the accompanying observational studies on CRPS. The remaining evidence from observational studies and case series shows promising results for DRG-S in PDN, focal neuropathy, and polyneuropathy, although quality appraisal per the GRADE criteria revealed very low-quality evidence for these indications. DRG-S for refractory postsurgical neuropathic pain in the groin (e.g., post-herniorrhaphy) or in the knee (e.g., post-TKA) has only been demonstrated in small-scale observational studies and future high-quality and adequately powered RCTs are warranted before widespread adoption or recommendation of this practice.

The authors still recommend offering first-line conventional therapy prior to DRG-S or other neuromodulation options. This involves incorporating a multimodal pharmacologic approach for chronic neuropathic pain [71] such as non-steroidal anti-inflammatory agents, gabapentinoids, antidepressants, and other pharmacotherapeutics. If conservative and pharmacologic options fail to provide adequate pain relief, pain specialists may consider offering neuromodulation options including dorsal column SCS, DRG-S, or peripheral nerve stimulation (PNS). The implanting physician may also pursue hybrid neuromodulation trials offering both DRG-S and dorsal column SCS to determine which modality offers better relief prior to implantation.

Unique Features of DRG-S Compared to Other Neuromodulation Interventions

Compared to traditional dorsal column SCS, DRG-S allows for more precise targeting of the DRG that innervates the targeted painful region without nonspecifically stimulating uninvolved dermatomes [4]. Furthermore, DRG-S allows for coverage of groin, pelvic, and foot pain, which is inconsistently treated and is difficult to capture using dorsal column SCS [4]. Finally, because the DRG has a thin layer of cerebrospinal fluid surrounding it, DRG-S maybe achieved with a much lower electrical current and is less impacted by positional changes [4]. Finally, some authors have postulated that analgesia may be achieved in both unstimulated regions and stimulated regions with DRG-S. This involves the concept of “cross-talk”, which involves the convergence between DRGs at adjacent levels, and thus placement of a DRG lead at one level may result in paresthesias and pain relief at adjacent levels [28, 70]. This may also involve contralateral segments due to crossover nerve fibers, as highlighted by a case [49] where unilateral DRG stimulation at the right T12 and S1 resulted in significant pain relief in the bilateral feet and low back. In this case [49], the authors hypothesized that the bilateral pain improvement, despite unilateral lead placement, was due to sympathetic modulation at the DRG with crossover fibers in the sympathetic chain and sacral plexuses. With the advent of PNS for treatment of chronic neuropathic pain syndromes [72], along with a unique profile and mechanism of action [73], implanting physicians may also offer this non-invasive neuromodulation intervention to patients instead of DRG-S. However, in certain more generalized distributions of pain, such as in CRPS which overlaps multiple nerve distributions, DRG-S may be advantageous instead of multiple PNS lead placements.

Proposed Mechanism of Action

The mechanism of analgesia via DRG-S involves reversal of the central pathophysiologic changes seen within the DRG neurons that perpetuate and amplify neuropathic pain [74]. As a response to the initial nerve injury, there is an inflammatory cascade that results from release of excitatory cytokines by immune cells and the supporting satellite glial cells [74]. Furthermore, genetic changes within the DRG neurons also lead to upregulation of ion channels and pain-related receptors and ligands [75], leading to alterations in ion current flux, decreased threshold for action potential firing, and impairment of the DRG’s ability to filter electrical impulses [76]. This mechanism may facilitate ectopic discharges that are relayed to the CNS and interpreted as pain [77].

In a painful state such as CRPS, the filtering across the T-junction of the DRG is decreased [78] along with hyperexcitability in the DRG. The analgesic effects of DRG-S in CRPS are postulated to be through the inhibition of noxious [70, 79, 80] and autonomic [81] afferent signals at the T-junction of the DRG and activation of endogenous opioid system in the dorsal horn [82, 83]. This inhibitory mechanism can attenuate wide-dynamic-range neuronal activity and decrease the windup phenomenon that is observed in CRPS [84].

In vitro and animal studies have also demonstrated that DRG-S can suppress inflammatory responses, even those driven by glial cells [85, 86]. In addition, DRG-S modulates the aberrant ion current flux [52, 87], stabilizes the cell membrane, and restores the DRG’s ability to impede ectopic discharges [79]. Thus, DRG-S normalizes the pathologic hypersensitivity of DRG neurons in neuropathic pain and offers analgesia.

Limitations and Future Directions

This review has several limitations. Clinical and methodological heterogeneity were substantial across included studies. Only one RCT was captured in the search strategy, and the remaining evidence comprised small-scale observational studies and case series/reports. Comparative arms and blinding are difficult to achieve in trials involving DRG-S.

Future studies should compare different waveforms and cost-effectiveness of DRG-S. Comparative studies between DRG-S and PNS for peripheral neuropathy are warranted. Finally, primary care clinicians and neurologists rarely consider DRG-S for treatment of neuropathic pain syndromes in their treatment algorithm. Therefore, dissemination of information and education for both physicians and patients via conference proceedings, social media coverage, and other avenues of information dissemination are important [88].

Conclusion

There is low-quality evidence highlighting that DRG-S is associated with improved pain intensity in lower extremity CRPS. Furthermore, there is very low-quality evidence highlighting that pain relief may be achieved with DRG-S for PDN, focal neuropathy, polyneuropathy, and postsurgical neuropathic pain of the groin and knee. Future high-quality and adequately powered RCTs within more homogeneous participant populations are warranted assessing the utility of DRG-S in lower extremity neuropathic pain syndromes.

Dorsal root ganglion stimulation (DRG-S) is a form of selective neuromodulation therapy that targets the dorsal root ganglion and offers analgesia in a variety of chronic pain conditions.

DRG-S is currently approved by the US Food and Drug Administration for the treatment of neuropathic pain associated with complex regional pain syndrome (CRPS) and/or causalgia in the groin and lower extremity.

The highest level of evidence is demonstrated with DRG-S use for CRPS of the lower extremity, although the quality of evidence was downgraded to “low” because of risk of bias, imprecision, heterogeneity, and indirectness from included observational studies.

There is very low-quality evidence demonstrating promising results for DRG-S in painful diabetic neuropathy, focal neuropathy, and polyneuropathy.

Efficacy of DRG-S for refractory postsurgical neuropathic pain of the groin (e.g., post-herniorrhaphy) or of the knee (e.g., post-total knee arthroplasty) has been demonstrated in small-scale observational studies.